Pharmalittle: Generic makers talk to feds about ending price-fixing probe
Hello, everyone, and how are you today? We are doing just fine, thank you, now that the Pharmalot campus has settled down. Our short person has left for the local schoolhouse for another day of learning and the official mascot is snoozing comfortably in a designated quiet corner. As for us, we are downing needed cups of stimulation — peppermint mocha is our preferred choice, so far — as we prepare for another round of phone calls and research. Meanwhile, we have assembled the usual menu of items to keep you engaged. Hope your day goes well and, as always, keep us in mind when something saucy occurs.
Several generic drug makers have held talks with the Department of Justice in the past six months about resolving a long-running criminal antitrust probe of alleged price-fixing by the companies, according to Bloomberg News. Among the possible outcomes that have been discussed are deferred prosecution agreements in which the companies would admit to certain allegations but would be shielded from indictment in exchange for cooperating with the investigation and paying fines.